New Treatment Lowers Heart Attack and Stroke Risk

For people with type 2 diabetes, heart problems are a major concern. A new treatment may help. Semaglutide reduces heart risks.

Semaglutide is a medication that helps people with type 2 diabetes. It reduces blood sugar and weight. Semaglutide also lowers heart risks like heart attacks and strokes. In a recent study, it reduced these risks by 14%. Semaglutide is the first oral medication of its kind to have this benefit. It works by acting like a natural hormone in the body. This hormone helps control blood sugar and appetite. Semaglutide is taken orally and can be used with other diabetes treatments. It helps people with type 2 diabetes at high risk of heart problems. The goal is to improve health outcomes and quality of life.

• Semaglutide approved for cardiovascular benefits.
• Reduces cardiovascular death, heart attack, and stroke.
• First GLP-1 RA with proven cardiovascular benefit.
• Approved for type 2 diabetes with high cardiovascular risk.
• Based on data from the SOUL trial.

This topic does not have distinct types or causes to categorize.

• Semaglutide reduces cardiovascular death, heart attack, and stroke by 14% in adults with type 2 diabetes at high cardiovascular risk.
• The SOUL trial data led to the approval of semaglutide for cardiovascular benefits, making it the first GLP-1 RA with proven blood glucose and body weight reduction, as well as cardiovascular benefits.
• Regulatory action in the U.S. is expected later this year, which may expand semaglutide's label to cover cardiovascular risk reduction.
• Novo Nordisk has sought approval for a 25 mg once-daily oral version of semaglutide for adults with obesity or overweight who also have cardiovascular disease.
• Semaglutide's approval highlights the importance of treatments that address both diabetes and heart problems to improve health outcomes and quality of life.
• Heart problems are the leading cause of disability and death for people living with type 2 diabetes, making cardiovascular benefits crucial for treatments.

• See a doctor if you have type 2 diabetes and are at high risk for cardiovascular disease.
• Seek immediate help when experiencing symptoms of a heart attack or stroke, such as chest pain or numbness in the face or arm.
• Consult a doctor if you are taking semaglutide and experience any side effects or have concerns about your treatment plan.

• Semaglutide reduces cardiovascular death, heart attack, and stroke by 14% in type 2 diabetes patients.
• The SOUL trial shows semaglutide's effectiveness in reducing cardiovascular risk.
• Semaglutide is the first oral GLP-1 RA with proven blood glucose and body weight reduction.
• The European Medicines Agency approved semaglutide for cardiovascular benefits in type 2 diabetes.
• Semaglutide treatment leads to improved health outcomes and quality of life for type 2 diabetes patients.

• European Medicines Agency
• National Institutes of Health
• Mayo Clinic